Oncology · Precision Cancer Testing

OncoTotal500
Comprehensive Genomic Profiling for Precision Oncology

Comprehensive genomic profiling (CGP) assay for advanced solid tumors that interrogates >500 cancer-associated genes and multiple biomarker classes from a single FFPE specimen.

FFPE tissue
Sample Type
1 FFPE block or 10–15 slides
Samples
14–21 working days
Turnaround Time

OncoTotal500 at Nucleome Informatics

Comprehensive Genomic Profiling for Precision Oncology

Why this Test Matters

Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.

Who Should Consider this Test

  • Advanced/metastatic solid tumors
  • Relapsed or refractory disease
  • Rare cancers
  • Patients being evaluated for targeted therapy, immunotherapy or clinical trials

Applicable Cancer Types

Lung, Breast, Colorectal, Ovarian, Prostate, Gastric, Pancreatic, Melanoma, Endometrial, Head & Neck, Brain, Sarcoma, Other solid tumors

What the test covers and delivers

What is Covered

  • 500+ genes
  • SNVs
  • InDels
  • CNVs
  • BRCA1/2 rearrangements
  • Gene fusions
  • MSI
  • TMB
  • LOH

Clinical Utility​

  • Treatment selection Prognostic and predictive biomarkers
  • Clinical trial matching
  • Identification of actionable
  • Alterations Comprehensive
  • Clinical interpretation

Technology

Comprehensive DNA and fusion profiling using high-depth NGS

Test specifications

ParameterDetails
Sample TypeFFPE tissue
Samples1 FFPE block or 10–15 slides
Turnaround Time14–21 working days
Report IncludesVariant interpretation, therapy associations, clinically actionable biomarkers
QualityHigh-depth NGS with rigorous QC
Talk to our team. Email info@nucleomeinfo.com or call +91 40 40114169 to discuss sample requirements and turnaround for OncoTotal500.